17 2025.06

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

03 2025.06

2025 ASCO ｜ Selected in Rapid Oral Abstract Presentation: Disitamab Vedotin as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer Achieves Efficacy Breakthrough

02 2025.06

2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer

27 2025.05

RemeGen’s Telitacicept Approved for Treatment of Myasthenia Gravis in China

12 2025.05

RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted

12 2025.05

Poised to Reshape Treatment Landscape: A Phase 3 Clinical Trial on Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

09 2025.05

RemeGen’s Disitamab Vedotin Gains Approval in China for its Third Indication Making it the First ADC Approved for HER2-Positive Advanced Breast Cancer with Liver Metastasis Globally

08 2025.05

Patients’ Visual Acuity Effectively Improved! Results Unveiled for the Phase II Clinical Study on RC28-E in Treating Diabetic Macular Edema | ARVO 2025

09 2025.04

Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis

14 2025.02

ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer